medcelerator · clinician one-pager
New Muscle-Targeted IV Treatment for SMA Ages 2 and Up
Isembyld (apitegromab-mstn) — a once-every-4-weeks IV medicine that targets muscle for people with SMA already on an SMN2 treatment
FDA Approved · United States · September 18, 2026
Condition: Spinal Muscular Atrophy
Who this is for
This is for children and adults living with SMA who are already on an SMN2-targeted treatment (such as nusinersen or risdiplam) and who may be candidates for labelled US Isembyld as a once-every-4-weeks IV add-on aimed at muscle. It explains the September 2026 FDA approval, the SAPPHIRE motor-function results, fracture cautions, Scholar Rock Supports navigation, and how to talk with an SMA clinician — without treating this as a replacement for Spinraza, Evrysdi, or gene therapy, a DIY import, or “approved” as funded. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
United States · Recruiting clinical trial
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Combination or different setting. Children under 2 on nusinersen or risdiplam; the label is age 2+ (phase 2).
https://clinicaltrials.gov/study/NCT07047144
See 1 trial on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=spinal%20muscular%20atrophy&intr=apitegromab&aggFilters=status:rec
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/isembyld-apitegromab